Novo touts SGLT2-topping data for blockbuster Victoza

SGLT2 drugs may be in the diabetes spotlight thanks to recent data showing that one of them--Eli Lilly ($LLY) and Boehringer Ingelheim's Jardiance--could cut cardiovascular risks. But Novo Nordisk ($NVO), maker of GLP-1 superstar Victoza, is striking back with some new data of its own. The company has rolled out a new meta-analysis showing that its therapy beat out SGLT2s at reducing the blood sugar metric HbA1c. More from FiercePharmaMarketing

Suggested Articles

Just one week after inking a COVID-19 vaccine deal with the U.S. for 100 million doses, J&J reached a supply agreement twice that size with the EU.

Ahead of a critical flu season, AstraZeneca is upping its manufacturing efforts to deliver more FluMist doses than previously anticipated.

FDA handed NS Pharma’s Viltepso a speedy FDA nod based on the same dystrophin production data that supported two Sarepta drugs' approvals.